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Abstract 
We investigated the effect of cyclic AMP (cAMP) on the pericellular fibrinolytic system in NY cells. Dibutyryl cAMP (dbcAMP) or 
forskolin increased the level of urokinase-type lasminogen activator (u-PA) mRNA and enhanced the secretion of u-PA antigen into the 
conditioned medium. These agents also increased u-PA antigen on the cell surface. PA inhibitor-1 (PAI-1) antigen was inhibited by 
dbcAMP or forskolin. Butyrate had no effect on the productionand secretion of u-PA and PAI-1. A binding assay of 125I-DFP-u-PA to 
NY cells revealed asingle class of binding sites with a K d of 3.85 nM and Bm~ x of 0.89" 105 binding sites/cell. The Bm~ was increased 
by dbcAMP (1 mM or 10 mM), forskolin (2 /zM or 20/zM) of 1.0-, 1.4-, 1.2- and 1.8-fold, respectively. However, the K d value was not 
changed. Furthermore, the level of mRNA for the u-PA receptor (u-PAR) was increased by these agents 1.2-, 1.7-, 1.8- and 2.5-fold, 
respectively. However, butyrate did not alter either the Bm~ or the u-PAR mRNA level. These results indicated that the pericellular 
fibrinolytic activity induced by u-PA/u-PAR is modulated by cAMP in osteoblast-like c lls. 
Keywords: Urokinase-type lasminogen activator (u-PA); Urokinase-type lasminogen activator receptor (u-PAR); Cyclic AMP (cAMP); (Human 
osteoblast-like cell) 
1. Introduction 
The fibrinolytic system is comprised of two enzymes: 
plasminogen activator (PA) and plasmin. Plasminogen ac- 
tivators (PAs) are serine proteases that activate the proen- 
zyme plasminogen i to a broad-spectrum serine protease, 
plasmin. There are two types of physiological PAs which 
are immunologically and biologically distinct: tissue-type 
plasminogen activator (t-PA) and urokinase-type lasmino- 
gen activator (u-PA). The former has higher affinity for 
fibrin and enhances the enzymatic activity in the presence 
of fibrin or fibrin degradation products. On the other hand, 
u-PA is predominantly involved in extravascular fibrinoly- 
sis that occurs in cell migration [1], in tissue remodelling 
[2], and in cell invasion and metastasis of cancer cells 
[3,4]. The PA-plasmin system has been implicated in 
turnover under physiological and pathological conditions 
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[5]. It has been described in mineralized tissues [6] and 
appears to be involved in the degradation of connective 
tissue [7]. Such PA activity is inactivated by its specific 
fast-acting inhibitor, PA inhibitor (PAl) which binds to and 
limits the activity of t-PA and u-PA. In such as plasma or 
synovial fluid, the balance between PAs and PAls regu- 
lates the level of fibrinolysis. 
Recently, the specific receptor for u-PA (u-PAR) has 
been identified in several cell types [8-10]. The cDNA for 
the u-PA receptor in U937 cells has been identified as well 
as the structure of the receptor itself [11]. The receptor 
recognizes the amino-terminal fragment of u-PA via the 
first repeated sequence in the receptor [12]. Therefore, the 
catalytic domain in the u-PA molecule is opened in free 
space and can express proteolytic activity on the cell 
surface. 
u-PA is secreted from the cells in a single-chain form 
(scu-PA), which binds to the receptor on the cell surface. 
After conversion to a two-chain form, u-PA remains at the 
cell surface by binding to the receptor, thus localizing the 
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enzymatic activity. The pericellular proteolytic activity 
which localizes PA activity on the cell surface is closely 
associated with cell migration, tumor invasion, tissue 
degradation or metastasis of tumor cells [1,3,4,13]. 
The bone resorbing factors, parathyroid hormone (PTH), 
prostaglandin E 2 (PGE 2) or interleukin-1 (IL-1), stimulate 
cAMP production in osteoblastic-like c lls [14,15]. Several 
reports have suggested that PA activity or PA antigen is 
enhanced by stimulating osteoblast-like or osteosarcoma 
cells with bone-resorbing factors [15-17]. However, the 
modulation of pericellular proteolysis in osteoblasts re- 
mains unclear and the effect of cAMP on the u-PA recep- 
tor in osteoblasts has not been investigated. In this study, 
the production and secretion of u-PA and PAI-1 from 
osteoblast-like cells were measured, and the effect of 
cAMP on u-PAR in osteoblast-like c lls was investigated. 
2. Materials and methods 
2.1. Reagents 
The following materials were purchased from the 
sources indicated: Forskolin, 2-o-dibutyryladenosine-3,5- 
cyclic monophosphate sodium salt (dbcAMP), butyrate and 
diisopropyl f uorophosphate (DFP) (Sigma, St. Louis, MO), 
Phosphatidylinositol-specific phospholipase C (PI-PLC) 
(Boehringer Mannheim, Germany), Eagle's MEM (Nissui 
Seiyaku, Tokyo), fetal calf serum (FCS) (Gibco, Grand 
Island, NY), bovine thrombin (Mochida Pharmaceut, 
Tokyo), plasminogen containing bovine fibrinogen 
(Organon Technika, Boxtel), Iodogen (Pierce Chemical 
Co., Rockford, IL), Na-.125I, [y-32p]ATP, [a-32p]dCTP 
(Amersham International,. Bucks, UK). The purified high 
molecular mass two-chain urokinase-type lasminogen ac- 
tivator was a gift from Dr. Nobuhara (Mochida Pharma- 
ceut., Tokyo). All other eagents and chemicals were of the 
highest grade available. 
2.2. Cell culture 
taining 10% FCS. After 48 h, the cells were washed twice 
with PBS (pH 7.4) and incubated in MEM without FCS for 
24 h of stimulation with or without dbcAMP, forskolin or 
butyrate. After harvesting the conditioned medium, u-PA 
bound to the cell membrane was recovered by incubating 
the cells with 50 mM glycine-HCl (pH 3.0) for 3 min. 
Thereafter, 100 mM Tris-HC1 (pH 8.0) was added to 
restore the pH to 7.4 [20] (This fraction is referred to 
below as the 'cell surface'). After removing the cell sur- 
face, the cells were rinsed with PBS and lysed with 0.5% 
Triton X-100. The conditioned medium, cell surface and 
cell lysate were analyzed by electrophoretic enzymography 
as follows. For preparation of the separation gel, 2 ml of 
acrylamide (30 g/100 ml) and bisacrylamide (1 g/100 
ml), 240 /xl of bovine plasminogen-rich fibrinogen (1.5 
mg/ml) and 1.5 ml of 1.5 M Tris-HCl buffer (pH 8.8) 
were mixed. Then, 24 ~1 of thrombin (10 NIH U/ml), 60 
/xl of 10% sodium dodecyl sulfate (SDS), 10% of 
N,N,N,N'-tetramethylethylenediamine (THEMED), and 60 
/zl of 10% ammonium peroxydisulfate w re further mixed. 
For preparation of the stacking el, the regular method was 
used. After electrophoresis, the gel was soaked in 2.5% 
Triton X-100 for 2 h, and incubated in 0.1 M glycine 
buffer (pH 8.3) at 37°C. After soaking in 50% trichloro- 
acetic acid (TCA) solution for 1 h, and in 7% ethanol for 1 
h, the gel was stained with Coomassie brilliant blue solu- 
tion. After destaining with 7% acetic acid, the gels so 
produced eveloped a lysis zone when plasminogen activa- 
tor was present in the sample solution. 
2.4. PI-PLC treatment of NY  cells 
NY cells were incubated in MEM without FCS for 24 h 
of stimulation with or without dbcAMP or forskolin. After 
harvesting the conditioned medium, cells were washed 
with PBS and treated with PI-PLC (0.2 IU/ml) for 1 h at 
37°C. Then, PA activity of the conditioned medium treated 
with PI-PLC was analyzed by the electrophoretic enzy- 
mography and compared with that of the cell surface 
fraction described above. 
The established osteohlast-like c ll line NY that origi- 
nated from human osteo,;arcoma [18] was a gift from the 
Japanese Cancer Researdl Resources Bank (Tokyo, Japan). 
The cells were cultured in Eagle's MEM, containing 10% 
fetal calf serum (FCS) at 37°C under a 5% CO 2 atmo- 
sphere. Cells were subcultured using 0.125% trypsin and 
0.5 mM Na2EDTA in calcium-and magnesium-free phos- 
phate-buffered saline (Plq',S). 
2.5. Measurements of u-PA antigen and PAl-1 antigen 
The amounts of u-PA antigen and PAI-1 antigen in the 
conditioned medium, cell surface or cell lysate were deter- 
mined by u-PA ELISA kit (Monozyme, Virum) and PAI-1 
ELISA kit (Technoclone, Vienna), respectively. 
2.6. Binding assay for u-PA to the osteoblast-like cells 
2.3. Measurements of PA activity in NY  cells 
Plasminogen activator activity and its molecular mass 
were analyzed by electrophoretic enzymography [19]. The 
osteoblast-like cells were subcultured at 1.8 × 10 5 
cells/well in 24-well culture plates in Eagle's MEM con- 
The purfied high molecular mass two-chain form of 
u-PA was treated with diisopropyl f uorophosphate (DFP), 
and radiolabeled using iodogen and Na-12sI (refered to 
below as 12SI-DFP-u-PA). The osteoblast-like c lls in 24- 
well multiplates were incubated with or without dbcAMP, 
forskolin or butyrate at 37°C for 24 h. Thereafter, u-PA 
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Table 1 
The amounts of  u -PA antigen in the osteoblast-l ike cell fractions after incubation with dbcAMP, forskolin or butyrate 
Conditioned medium Cell surface Cell lysate 
Control 6.79 + 1.66 a 5.11 + 0.21 21.89 + 2.29 
dbcAMP 1 mM 8.16 5- 1.32 6.83 + 1.47 21.61 + 3.24 
10 mM 13.03 5- 0.84 * * 7.21 5- 0.48 * * 23.55 5- 2.67 
Forskolin 2 /xM 10.16 5- 0.84 * 7.83 + 0.31 * * 26.78 5- 1.15 * * 
20 /zM 11.41 + 0.58 * * 8.75 + 0.33 * * 30.92 + 2.74 * * 
Butyrate 7.16 + 0.99 4.67 + 1.44 20.77 -I- 2.39 
a ng /1 .8  × 105 cells. The osteoblast-l ike cells were incubated with dbcAMP, forskolin or butyrate for 24 h, and the conditioned medium, cell surface or 
cell lysate were obtained as described in Section 2. The results are expressed as mean values with standard deviation. The values represent four 
experiments. * P < 0.05, * * P < 0.01. 
bound to the cell membrane was released by acid treatment 
as described above. 125I-DFP-u-PA (0-15 nM) with or 
without excess unlabeled u-PA (3000 nM) was added to 
the cells in 24-well multiplates. The binding reaction pro- 
ceeded at 4°C for 90 min. The radioactivity in the cells that 
were lysed with 0.5% Triton X-100, was measured with a 
multi-crystal gamma counter LB-2100 (Berthold, Wikd- 
bad). The binding characteristics of u-PA to the cells were 
examined by a Scatchard analysis [21]. 
2.7. Northern blot analysis for u-PA mRNA and u-PAR 
mRNA 
u-PAR oligonucleotide probe corresponding to 1-15 
amino acids of u-PAR [11] was synthesized and radiola- 
beled with ['y-32p]ATP. NY cells were cultured at 1 × 107 
cells in a 75 cm 2 tissue culture flask. The cells were 
incubated with or without dbcAMP, forskolin or butyratee 
for 8 h. After incubation, total RNA was extracted from 
the cells by the acid guanidinium thiocyanate-phenol-chlo- 
roform extraction method [22]. Total RNA (15 /zg/lane) 
was electrophoresed on formaldehyde agarose and trans- 
ferred to a BA 85 membrane (Schleicher and Schuell, 
Dassel). Hybridization was performed using labeled human 
cDNA probe specific to u-PA and synthetic oligonucleo- 
tide probe specific to u-PAR. The membrane was then 
washed three times for 30 min at 50°C in 2 × SSC contain- 
ing 0.1% SDS and used for autoradiography. As the 
control for these experiments, human fl-actin cDNA probe 
was used and the amounts of u-PA mRNA and u-PAR 
mRNA were corrected according to the content of /3-actin 
mRNA. 
3. Results 
3.1. The production and secretion of u-PA antigen and 
PAI-1 antigen after incubating NY cells with dbcAMP, 
foskolin or butyrate 
To clarify the effect of cAMP on the secretion of u-PA 
antigen, the osteoblast-like c lls were incubated with db- 
cAMP (1 mM, 10 mM), forskolin (2 /~M, 20 /zM) or 
butyrate (10 mM) for 24 h at 37°C. As shown in Table 1, 
dbcAMP (10 mM), forskolin (2/zM, 20/xM) significantly 
enhanced the secretion of u-PA antigen into the condi- 
tioned medium. After stimulation with I mM dbcAMP, the 
level of u-PA antigen was slightly increased. In the cell 
surface fraction which was recovered from the cell mem- 
brane by acid treatment, and in the cell lysate, the level of 
u-PA antigen was increased significantly by 10 mM db- 
cAMP and by 2 or 20 ~M forskolin. However, the amount 
of u-PA antigen in the conditioned medium, cell surface or 
cell lysate were not changed by butyrate. 
PAI-1 antigen was significantly decreased after stimula- 
tion with dbcAMP or forskolin in the conditioned medium 
or cell lysate (Table 2). Butyrate had no effect on the 
production and secretion of PAI-1. PAI antigen was unde- 
tectable on the cell surface. 
3.2. u-PA activity after stimulation with dbc AMP, foskolin 
or butyrate 
The u-PA activity was measured by electrophoretic 
enzymography (Fig. 1). The conditioned medium exhibited 
major and minor lysis bands at M r 55 and at 33 kDa, 
respectively. In the cell surface and cell lysate, only the 
minor lysis band at M r 55 kDa appeared. In the presence 
of anti-u-PA IgG, all lysis bands disappeared (lanes 8). 
Thus, NY cells produce and secrete u-PA, and u-PA 
Table 2 
The amounts of  PAI-1 antigen in the osteoblast-l ike cell fractions after 
incubation with dbcAMP,  forskolin or butyrate 
Condit ioned Cell Cell lysate 
medium surface 
Control 128.25 + 19.03 a _ 47.67 5- 3.39 
dbcAMP 1 mM 79.255-9.76 * * - 21 .67+3.21  * * 
10 mM 57.505-5.68 * * - 30.665-12.68 * 
Forskolin 2 /zM 93.75 5-12.25 * - 31.33 5- 5.91 * * 
20 /xM 75.005-10.51 * * - 25.335-4.99 * * 
Butyrate 114.65 5-10.42 - 43.67 5- 3.30 
a ng//1.8X 105 cells. The osteoblast-l ike cells were incubated with db- 
cAMP, forskolin or butyrate for 24 h, and the condit ioned medium, cell 
surface or cell lysate were obtained as described in Section 2. The results 
are expressed as mean values with standard eviation. The values repre- 
sent four experiments. * P < 0.05, * * P < 0.01, - ,  not detected. 
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activity was observed on the cell surface. The activity of 
t-PA was undetectable in all fractions. 
In the conditioned medium (Fig. 1A), u-PA activity was 
remarkably enhanced by 113 mM dbcAMP and 2 or 20/xM 
forskolin (lanes 4-6). The: activity was increased slightly 
by 1 mM dbcAMP (lane 3). The activity of u-PA on the 
cell surface is shown in Fig. lB. There was remarkable 
increase in u-PA activity on the cell surface in the pres- 
ence of dbcAMP or for,~kolin (lanes 3-6). In the cell 
lysate, stimulation with dbcAMP or forskolin, lysis bands 
at 55 kDa were increased and minor lysis bands at 33 kDa 
were detected (Fig. 1C, laaes 3-6). Butyrate had no effect 
on u-PA activity in the condition medim (lanes 7), cell 
surface or cell lysate well as upon u-PA antigen. 
A 
55 kDa - 
33 kDa - 
1 2 3 4 5 6 7 8 
B 
55 kDa - 
33 kDa - 
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Fig. 1. The activity of  u-PA in osteoblast-like cells. Electrophoretic 
enzymography of  the conditioned medium (A), cell surface (B) and cell 
lysate (C) of the osteoblast-like c lls. The cells were cultured in MEM 
without FCS for 24 h with dbcAMP, forskolin or butyrate. The gels were 
incubated with 0.1 M glycine-NaOH buffer (pH 8.3) at 370C for 24 h. 
Lanes: 1, u-PA; 2, control; 3, 1 mM dbcAMP; 4, 10 mM dbcAMP; 5, 2 
/.LM forskolin; 6, 20/,tM forskolin; 7, 10 mM butyrate; 8,control treated 
with anti-u-PA IgG. 
55 k Da - 
33 kDa - 
1 2 3 4 5 6 7 8 
Fig. 2. The u-PA activity in the conditioned medium of osteoblast-likc 
cells treated with PI-PLC. After harvesting the conditioned medium 
which was incubated with or without dbcAMP or forskolin, the cells were 
treated with PI-PLC (0.2 IU/ml) for 1 h. Lanes: 1, u-PA; 2, cell surface 
fraction obtained after acid treatment; 3, conditioned medium of PI-PLC- 
treated cells; 4, conditioned medium of PI-PLC-treated cells after acid 
treatment; 5, acid treatment after stimulation with 10 mM dbcAMP; 6, 
PI-PLC treatment after stimulation with 10 mM dbcAMP; 7, acid treat- 
ment after stimulation with 20 /xM forskolin; 8, PI-PLC treatment after 
stimulation with 20 p~M forskolin. 
The PI-PLC treatment of NY cells released the u-PA 
into the conditioned medium (Fig. 2, lane 3). The released 
u-PA activity increased by the stimulation with dbcAMP 
or forskolin (Fig. 2, lanes 6 and 8). These changes in u-PA 
activity obtained in the PI-PLC treated cells were very 
similar to those in the cell surface fraction (Fig. 2, lane 2 
for control, lane 5 for dbcAMP stimulation, lane 7 for 
forskolin stimulation). When the cell surface fraction was 
obtained from PI-PLC-treated NY cells, only trace activity 
was observed (Fig. 2, lane 4), indicating that u-PA does 
not exist at the cell menbrane. 
3.3. Binding of 125I-u-PA to the osteoblast-like c lls 
The binding of u-PA to the osteoblast-like cells was 
analyzed using 125I-DFP-u-PA. The specific binding of 
u-PA to the cells was obtained by subtracting the non- 
specific from the total binding (Fig. 3A). The nature of the 
binding was investigated by Scatchard analysis. Since a 
single line was obtained in the Scatchard plot (Fig. 3B), 
the osteoblast-like cells possess a single class of binding 
sites for u-PA. The binding parameters are shown in Table 
3. After stimulating the osteoblast-like cells with 1 mM 
dbcAMP or 2 /xM forskolin, the K d values were slightly 
decreased. However, 10 mM dbcAMP or 20 /zM forskolin 
did not change the K d values. On the other hand, the Bma X 
was significantly increased by 10 mM dbcAMP and by 2 
or 20 /~M forskolin. When the osteoblast-like cells were 
stimulated by butyrate, neither the K d nor the Bma x were 
changed. 
3.4. Effect of cAMP on mRNA for u-PA and u-PA receptor 
Since u-PA binds to specifically osteoblast-like cells, 
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Fig. 3. The binding of 125I-DFP-u-PA to the osteoblast-like cells. Os- 
teoblast-like cells (1.8 × 105) were incubated with dbcAMP, forskolin or 
butyrate in MEM without FCS for 24 h at 37°C. A indicates the specific 
binding curve. B indicates the Scatchard analysis. ( I ) ,  control; (O), 1 
mM dbcAMP treatment; (A), 10 mM dbcAMP treatment; ( , ) ,  2 /xM 
forskolin treatment; (t2), 20 /.~M forskolin treatment; (©), 10 mM 
butyrate. 
using a synthetic oligonucleotide. A probe was synthesized 
corresponding to 1-15 amino acids of the u-PA receptor 
from U937 cells. Northern blot analysis with 32 P-labeled 
synthetic oligonucleotide probe revealed a hybridizing band 
of 1.4 kb. Thus, the osteoblast-like c lls expressed u-PAR 
mRNA. 
In further analyzing the effect of cAMP on u-PA and 
u-PA receptor, total RNA isolated from osteoblast-like 
Table 3 
The binding parameters of 125I-DFP-u-PA to the osteoblast-like cells 
incubation with dbcAMP, forskolin or butyrate 
K d (nM) B=., 5 (10 binding sites/cell) 
Control 3.85 + 0.33 0.89 + 0.06 
dbcAMP 1 mM 3.08+0.42 * 0.89+0.08 
10mM 3.91+0.11 1.26+0.03 * * 
Forskolin 2 /xM 3.37+0.09 * 1.11+0.02 * * 
20/xM 3.45-t-0.22 1.60+0.05 * * 
Butyrate 3.32 -I- 0.93 0.79 + 0.19 
The osteoblast-like cells were incubated with dbcAMP, forskolin or 
butyrate for 24 h. 125I-u-PA (0-15 nM) with or without excess unlabeled 
u-PA (3000 nM) was added to the cells. The binding characteristics of
u-PA to the cells were examined by Scatchard analysis. The results are 
expressed as mean values with standard eviation. The values represent 
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Fig. 4. The effects of dbcAMP, forskolin or butyrate on u-PA mRNA and 
u-PAR mRNA upon the osteoblast-like c lls. Osteoblast-like cells were 
incubated with dbcAMP, forskolin or butyrate for 8 h and 15/zg of total 
RNA was Northern blotted to identify for u-PA (A) and u-PAR (B). The 
densitometric data of u-PA mRNA and u-PAR mRNA were divided by 
those of fl-actin mRNA. Lanes: 1, control; 2, 1 mM dbcAMP; 3, 10 mM 
dbcAMP; 4, 2 /~M forskolin; 5, 20 /xM forskolin; 6, 10 mM butyrate. 
cells, treated and untreated with dbcAMP, forskolin or 
butyrate was hybridized with labeled RNA transcripts pre- 
pared from u-PA and u-PAR cDNA. Fig. 4 shows that 
dbcAMP or forskolin considerably elevated the 2.5 kb 
u-PA mRNA (Fig. 4A) and the 1.4 kb u-PAR mRNA (Fig. 
4B) level. When the osteoblast-like c lls were stimulated 
with 1 or 10 mM dbcAMP, or 2 or 20 /xM forskolin, 
compared with untreated cells (lane 1), the ratio of u-PAR 
mRNA/fl-actin mRNA increased 1.2-, 1.7-, 1.8- and 2.5- 
fold, respectively. Further, the ratio of u-PA mRNA/fl- 
actin mRNA increased 1.3-, 1.4-, 1.2- and 2.8-fold after 1 
or 10 mM dbcAMP, or 2 or 20/~M forskolin, respectively. 
Thus, the increase in u-PA mRNA was correlated with that 
of u-PA activity. However, butyrate (lane 6) had no signif- 
icant effect on the induction of 2.5 kb u-PA mRNA and 
1.4 kb u-PAR mRNA in these cells. 
4. Discussion 
Osteoblast cells are involved in osteoclast formation, 
and several cytokines or growth factors contribute to bone 
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resorption [23]. Recent slEudies of pericellular proteolysis 
have identified a regulatory mechanism based upon a 
specific u-PA receptor [1,10,12,24]. To assess the peri- 
cellular proteolysis in bone resorption, the mode of PA 
production, as well as its specific receptor were investi- 
gated in the osteoblast-like c ll line. 
The distribution of u-PA was examined in not only the 
conditioned medium and cell lysate, but also on the cell 
surface. The cell surface samples contained u-PA bound on 
the cell membrane, which was released by acid treatment. 
The u-PA antigen was present in three fractions from NY 
cells (Table 1), and u-PA was predominant in the cell 
lysate and a small amount was found on the cell surface. 
Intracellular signal transduction for u-PA secretion was 
investigated by incubating the osteoblast-like cells with 
dbcAMP or forskolin. DbcAMP and forskolin which in- 
crease cAMP, increased the secretion of both u-PA antigen 
(Table 1) and u-PA activity (Fig. 1) in the conditioned 
medium. Kooistra et al. have suggested that butyrate in- 
creases t-PA and PAl-] secretion, and increases t-PA 
mRNA levels in human endothelial cells [25]. However, in 
NY cells, u-PA antigen and its activity in the conditioned 
medium, cell surface or cell lysate were not affected by 
butyrate. 
When incubated with the cells after exposure to acid, 
which exposes all the receptors on the cell membrane, 
125I-DFP-u-PA bound NY cells specifically and saturably 
(Fig. 3), indicating the presence of a specific u-PA recep- 
tor. As a single straight line was obtained by the Scatchard 
analysis, only one class of receptor is present on the cell 
membranes. The number of receptors for u-PA (Table 3) 
was not affected by butyrate, but was enhanced about 1.4-, 
1.2- and 1.8-fold by 10 mM dbcAMP and 2 or 20 /xM 
forskolin, respectively. The K d values after stimulation 
with 1 mM dbcAMP or 2 /xM forskolin were decreased. 
However, 10 mM dbcAMP, 20 /xM forskolin or butyrate 
did not change the K d values. Therefore, the number of 
u-PA binding sites in the cell surface, were increased 
without changing the K d values, by increasing the intra- 
or extracellular cAMP concentration i  the osteoblast-like 
cells. 
Northern blotting analysis revealed the presence of 
u-PAR mRNA (about 1.4 kb) in the osteoblast-like c lls, 
the size of u-PAR mRNA was the same as that in U937 
cells [26]. These results suggest hat NY cells express 
u-PA receptor. In U937 cells, phorbol myristate acetate 
(PMA), an activator of protein kinase C (PKC), increased 
the number of u-PAR [27,28] and u-PAR mRNA [26]. In 
the human glomerular epithelial cell line, E71 A1, en- 
dothelin-1 increases both the number of u-PAR and u-PAR 
mRNA [29]. However, the regulation of u-PAR by cAMP 
in osteoblasts has not been investigated. In this study, 
u-PAR mRNA levels were increased 1.2-, 1.7-, 1.8- and 
2.5-fold by 1 or 10 mM dbcAMP and 2 or 20 ~M 
forskolin, respectively. However, u-PAR mRNA and the 
number of u-PAR receptors were not affected by butyrate. 
Thus, in the osteoblast-like c lls, the mode of alteration in 
the number of u-PAR on the cell surface after stimulation 
with dbcAMP or forskolin, correlated well with that in 
u-PAR mRNA. Fukumoto et al. have suggested that 
forskolin and PTH have the same effects on fibrinolytic 
factors mRNA synthesis in normal and malignant os- 
teoblasts, and these results strongly suggest hat the effect 
of PTH on fibrinolytic factors protein is mediated by 
cAMP [17]. The increase of intracellular cAMP by either 
dbcAMP or forskolin stimulation may further activate the 
intracellular signal transduction system, which is followed 
by protein synthesis in osteoblast-like cells. However, 
further studies are required clarify the molecular mecha- 
nism of such a series of intracellular events. Thus, peri- 
cellular enzymatic activity is regulated by u-PA bound to a 
specific receptor expressed on the cell surface. 
The results of several studies [15,16,30] have shown 
that osteosarcoma and osteoblast-like cells from human 
and rat calvaria behave in a similar manner. Therefore, the 
regulation of u-PA and u-PAR in the osteoblast-like c lls 
may represent the physiological mode of their regulation in 
osteoblasts. Thus, the osteoblast-like cells secrete u-PA, 
which binds to u-PAR on the cell membrane and expresses 
u-PA activity. Moreover, u-PAR mRNA levels were en- 
hanced by dbcAMP or forskolin, which increase cAMP 
levels. The increased expression of u-PA as well as u-PAR 
enhances pericellular proteolytic activity. Since plasmino- 
gen activation is defined by the ratio of PA to PAl, the 
decrease of PAl after dbcAMP or forskolin treatment of 
osteoblast-like cells contributes further enhancement of
pericellular proteolysis. Such enzymatic activity related 
with u-PAR may contribute to bone resorption. Further 
studies are needed to show whether or not changes in both 
PA/PAI activity and the pericellular proteolytic role played 
by u-PAR are also important for the initiation of bone 
resorption. 
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